Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has been extensively studied for its effects on weight management and metabolic health. In the SURMOUNT-1 clinical trial, published in The New England Journal of Medicine (2022), participants with obesity but without diabetes achieved average weight reductions of 15–21% over 72 weeks, depending on the dosage used. This degree of weight loss surpasses many existing pharmacologic interventions, making tirzepatide a promising compound in the research of obesity treatment.
Beyond weight reduction, tirzepatide has also shown strong benefits in type 2 diabetes management. In the SURPASS trials, patients receiving tirzepatide achieved significant improvements in HbA1c levels (up to a 2.4% reduction), alongside enhanced insulin sensitivity and better overall glycemic control. Research has also highlighted potential improvements in cardiometabolic risk factors, such as blood pressure and lipid profiles, suggesting broader applications for metabolic syndrome and cardiovascular health research.
140 $
Fast Shipping
Most orders are processed out the same day they are placed.
It is important to stress that tirzepatide, while backed by encouraging clinical trial data, is still being studied for its full range of effects and long-term safety. At this time, its use outside of controlled settings is not approved, and it is designated for research purposes only.
Application
• Supports Weight Management • May Improve Type 2 Diabetes Control • Enhances Insulin Sensitivity • Helps Regulate Blood Glucose • May Improve Cardiometabolic Health • Potential Applications in Metabolic Syndrome and Cardiovascular Research
